Stock 4591 RIBOMIC INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Ribomic Inc.

Equities

4591

JP3974850004

Market Closed - Japan Exchange
Other stock markets
 01:59:56 2024-05-24 EDT 		5-day change 1st Jan Change
83 JPY -1.19% Intraday chart for Ribomic Inc. -1.19% -23.15%
03-07 Ribomic Inc. announced that it has received ¥4.192212 million in funding from SMBC Nikko Securities Inc. CI
02-20 Ribomic Inc. announced that it expects to receive ¥4.192212 million in funding from SMBC Nikko Securities Inc. CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ribomic Inc. announced that it has received ¥4.192212 million in funding from SMBC Nikko Securities Inc.
CI
Ribomic Inc. announced that it expects to receive ¥4.192212 million in funding from SMBC Nikko Securities Inc.
CI
Ribomic Inc. Reports Earnings Results for the Nine Months Ended December 31, 2023
CI
Ribomic and Ajinomoto Co. Partner for Nucleic Acid Aptamer Research
MT
Ribomic Enters Into Drug Research Collaboration with Ajinomoto
MT
RIBOMIC Inc. and Ajinomoto Co., Inc. Announce Joint Research Agreement
CI
RIBOMIC Phase I and II Data Published in the Eye: Full TOFU/RAMEN/TEMPURA Trial Results Demonstrate Clinical Proof of Concept of Umedaptanib Pegol in Exudative Age-Related Macular Degeneration (nAMD)
BU
RIBOMIC Phase I and II Data Published in the Eye
CI
Ribomic Inc. Reports Earnings Results for the Half Year Ended September 30, 2023
CI
Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2024
CI
Ribomic Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023
CI
Ribomic Inc. Reports Earnings Results for the Full Year Ended March 31, 2023
CI
Ribomic Inc. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024
CI
Ribomic Inc. Reports Earnings Results for the Full Year Ended March 31, 2023
CI
RIBOMIC, Inc. Announces Start of Administration of RBM-007, Achondroplasia Investigational Drug, to the First Patient in the Early Phase II Study in Japan
CI
Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2023
CI
Ribomic Inc. Reports Earnings Results for the Nine Months Ended December 31, 2022
CI
Ribomic Signs JV MoU for Development of RBM-007 Aptamer in China; Shares Rise 3%
MT
RIBOMIC Announces MOU to Establish Joint Venture for Development of RBM-007 in China
CI
Japan Stocks Buried under Persistent US Monetary Tightening; Eisai Tanks 6% as Alzheimer's Trial Death Count Rises to Two
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4591 Stock
  4. News Ribomic Inc.